Article info

PDF
Original article
Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of acute ST-segment elevation myocardial infarction
  1. Correspondence to Dr Matthias Schwenkglenks, University of Basel, Institute of Pharmaceutical Medicine (ECPM), Klingelbergstrasse 61, 4056 Basel, Switzerland; m.schwenkglenks{at}unibas.ch
View Full Text

Citation

Schwenkglenks M, Toward TJ, Plent S, et al
Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of acute ST-segment elevation myocardial infarction

Publication history

  • Accepted January 5, 2012
  • First published February 7, 2012.
Online issue publication 
March 15, 2012

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.